D. E. Shaw & Co., Inc. Idera Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$1.06 - $2.15 $116,634 - $236,570	-110,033 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$1.45 - $2.79 $7,587 - $14,600	-5,233 Reduced 4.54%	110,033 $200,000
Q3 2019 Nov 14, 2019	SELL	$2.12 - $3.31 $92,128 - $143,842	-43,457 Reduced 27.38%	115,266 $333,000
Q2 2019 Aug 14, 2019	BUY	$2.37 - $3.97 $144,366 - $241,828	60,914 Added 62.28%	158,723 $424,000
Q1 2019 May 15, 2019	BUY	$2.33 - $3.79 $102,354 - $166,490	43,929 Added 81.53%	97,809 $249,000
Q4 2018 Feb 14, 2019	BUY	$2.77 - $9.38 $27,567 - $93,349	9,952 Added 22.66%	53,880 $149,000
Q3 2018 Nov 14, 2018	BUY	$5.53 - $11.36 $242,921 - $499,022	43,928 New	43,928 $391,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.